Biomarker-Driven Personalized Immunoprevention: Toward More Efficient Clinical Trials?
Cancer Prev Res (Phila)
; 17(9): 399-400, 2024 Sep 04.
Article
in En
| MEDLINE
| ID: mdl-38884213
ABSTRACT
In this secondary analysis of specimens from the CANTOS trial, the investigators find that patients with clonal hematopoiesis mutations, particularly in the TET2 gene, predict a benefit of decreased cancer risk with the administration of the anti-IL1ß agent canakinumab. Despite small numbers and the need for prospective validation, the findings are exciting as they demonstrate the potential for personalized chemoprevention approaches. Such personalized approaches can potentially enhance the feasibility of cancer prevention trials. See related article by Woo et al., p. 429.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Biomarkers, Tumor
/
Precision Medicine
/
Antibodies, Monoclonal, Humanized
Limits:
Humans
Language:
En
Journal:
Cancer Prev Res (Phila)
Journal subject:
NEOPLASIAS
Year:
2024
Document type:
Article
Country of publication:
United States